Primary Endpoints In Updated Analysis Of Pivotal Trial Of Recell System For Soft Tissue Repair
09/11/2022 23:47
Nov 9 (Reuters) - AVITA Medical Inc RCEL.O :
* AVITA MEDICAL ANNOUNCES ACHIEVEMENT OF CO-PRIMARY
ENDPOINTS IN
UPDATED ANALYSIS OF PIVOTAL TRIAL OF RECELL® SYSTEM FOR SOFT
TISSUE REPAIR
* AVITA MEDICAL INC - LOOK FORWARD TO SHARING SOFT TISSUE
REPAIR
OUTCOMES WITH FDA VIA OUR PMA SUBMISSION EXPECTED IN DECEMBER
2022
Source text for Eikon: ID:nGNXbW6f6L
Further company coverage: RCEL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on AVITA Medical
See all newsAvita Medical Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Avita Medical Inc Expected To Post A Loss Of 29 Cents A Share: Earnings Preview
Brief: AVITA Medical Q1 EPS USD -0.35
Brief: AVITA Medical Q4 EPS USD -0.38
Brief: Avita Medical Inc - Enters Into Credit Agreement And Guaranty - SEC Filing